Stabilization of Breast Cancer Xenograft Tumour Neovasculature by Angiopoietin-1

Overview

Journal Br J Cancer

Specialty Oncology

Date 2002 Mar 1

PMID 11870550

Citations 27

Authors

S Tian

A J Hayes

L-Y Li

Affiliations

Soon will be listed here.

Abstract

Angiopoietin-1 is a promoter of physiological vasculogenesis and angiogenesis because it induces vascular branching and smooth muscle recruitment to newly formed blood vessels. However, angiopoietin-1 expression in tumours appears to be uncommon, and angiopoietin-1 overexpression in cancer cells has been reported to lead to inhibition of xenograft tumour growth. We report here that angiopoietin-1 overexpression resulted in stabilization of tumour edge-associated blood vessels, as it prevented vessel dilation and dissociation of smooth muscle cells from existing vessels. In addition, angiopoietin-1 stimulated an infiltration of mesenchymal cells into the tumours, such that the coverage of microvessels by pericytes increased markedly, and the cancer cells were separated into small masses by the host stroma. The rates of both cancer cell proliferation and apoptosis decreased significantly in the presence of angiopoietin-1. Tie2, the receptor for angiopoietin-1, was found to be present in vascular smooth muscle cells in culture in addition to endothelial cells. These findings suggest that a vascular stabilization effect of angiopoietin-1 accounts for the inhibition of tumour growth.

Citing Articles

TNFSF15 facilitates the differentiation of CD11b myeloid cells into vascular pericytes in tumors.

Gu X, Zhu Y, Zhao C, Cao Y, Wang J, Zhang Q Cancer Biol Med. 2023; 20(11).

PMID: 37921408 PMC: 10690882. DOI: 10.20892/j.issn.2095-3941.2023.0245.

Protective effect of COMP-angiopoietin-1 on peritoneal vascular permeability and peritoneal transport function in uremic peritoneal dialysis rats.

Shi Y, Xiong Y, Lei Y, Li Z, Yan H, Yuan J Am J Transl Res. 2019; 11(9):5932-5943.

PMID: 31632561 PMC: 6789243.

Different patterns of inflammatory and angiogenic factors are associated with peritoneal small solute transport and peritoneal protein clearance in peritoneal dialysis patients.

Shi Y, Yan H, Yuan J, Zhang H, Huang J, Ni Z BMC Nephrol. 2018; 19(1):119.

PMID: 29792163 PMC: 5966920. DOI: 10.1186/s12882-018-0921-6.

Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer.

Wu F, Paez-Ribes M, Xu P, Man S, Bogdanovic E, Thurston G Sci Rep. 2016; 6:36694.

PMID: 27841282 PMC: 5107907. DOI: 10.1038/srep36694.

Anti-vascular effects of the cytosolic phospholipase A2 inhibitor AVX235 in a patient-derived basal-like breast cancer model.

Kim E, Tunset H, Cebulla J, Vettukattil R, Helgesen H, Feuerherm A BMC Cancer. 2016; 16:191.

PMID: 26951085 PMC: 4782288. DOI: 10.1186/s12885-016-2225-1.

References

Hayes A, Huang W, Yu J, Maisonpierre P, Liu A, Kern F . Expression and function of angiopoietin-1 in breast cancer. Br J Cancer. 2000; 83(9):1154-60. PMC: 2363588. DOI: 10.1054/bjoc.2000.1437. View

Kukk E, Wartiovaara U, Gunji Y, Kaukonen J, Buhring H, Rappold I . Analysis of Tie receptor tyrosine kinase in haemopoietic progenitor and leukaemia cells. Br J Haematol. 1997; 98(1):195-203. DOI: 10.1046/j.1365-2141.1997.1732989.x. View

Leiser R, Luckhardt M, Kaufmann P, Winterhager E, Bruns U . The fetal vascularisation of term human placental villi. I. Peripheral stem villi. Anat Embryol (Berl). 1985; 173(1):71-80. DOI: 10.1007/BF00707305. View

Maisonpierre P, Suri C, Jones P, Bartunkova S, Wiegand S, Radziejewski C . Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997; 277(5322):55-60. DOI: 10.1126/science.277.5322.55. View

Spitznas M, Reale E . Fracture faces of fenestrations and junctions of endothelial cells in human choroidal vessels. Invest Ophthalmol. 1975; 14(2):98-107. View

Tanaka S, Mori M, Sakamoto Y, Makuuchi M, Sugimachi K, Wands J . Biologic significance of angiopoietin-2 expression in human hepatocellular carcinoma. J Clin Invest. 1999; 103(3):341-5. PMC: 407900. DOI: 10.1172/JCI4891. View

Pettersson A, Nagy J, Brown L, Sundberg C, Morgan E, Jungles S . Heterogeneity of the angiogenic response induced in different normal adult tissues by vascular permeability factor/vascular endothelial growth factor. Lab Invest. 2000; 80(1):99-115. DOI: 10.1038/labinvest.3780013. View

Suri C, McClain J, Thurston G, McDonald D, Zhou H, Oldmixon E . Increased vascularization in mice overexpressing angiopoietin-1. Science. 1998; 282(5388):468-71. DOI: 10.1126/science.282.5388.468. View

Bunone G, Vigneri P, Mariani L, Buto S, Collini P, Pilotti S . Expression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological features. Am J Pathol. 1999; 155(6):1967-76. PMC: 1866941. DOI: 10.1016/S0002-9440(10)65515-0. View

10.

Dumont D, Gradwohl G, Fong G, Auerbach R, Breitman M . The endothelial-specific receptor tyrosine kinase, tek, is a member of a new subfamily of receptors. Oncogene. 1993; 8(5):1293-301. View

11.

Folkman J, DAmore P . Blood vessel formation: what is its molecular basis?. Cell. 1996; 87(7):1153-5. DOI: 10.1016/s0092-8674(00)81810-3. View

12.

Eggert A, Ikegaki N, Kwiatkowski J, Zhao H, Brodeur G, Himelstein B . High-level expression of angiogenic factors is associated with advanced tumor stage in human neuroblastomas. Clin Cancer Res. 2000; 6(5):1900-8. View

13.

Martoglio A, Tom B, Starkey M, Corps A, Charnock-Jones D, Smith S . Changes in tumorigenesis- and angiogenesis-related gene transcript abundance profiles in ovarian cancer detected by tailored high density cDNA arrays. Mol Med. 2000; 6(9):750-65. PMC: 1949983. View

14.

Gavrieli Y, Sherman Y, Ben-Sasson S . Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J Cell Biol. 1992; 119(3):493-501. PMC: 2289665. DOI: 10.1083/jcb.119.3.493. View

15.

Wong M, Chan S, Fu K, Leung S, Cheung N, Yuen S . The angiopoietins, tie2 and vascular endothelial growth factor are differentially expressed in the transformation of normal lung to non-small cell lung carcinomas. Lung Cancer. 2000; 29(1):11-22. DOI: 10.1016/s0169-5002(00)00118-5. View

16.

Dvorak H, Sioussat T, Brown L, Berse B, Nagy J, Sotrel A . Distribution of vascular permeability factor (vascular endothelial growth factor) in tumors: concentration in tumor blood vessels. J Exp Med. 1991; 174(5):1275-8. PMC: 2118980. DOI: 10.1084/jem.174.5.1275. View

17.

Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86(3):353-64. DOI: 10.1016/s0092-8674(00)80108-7. View

18.

Spagnoli L, Villaschi S, Neri L, Palmieri G, Taurino M, Faraglia V . Autoradiographic studies of the smooth muscle cells in human arteries. Paroi Arterielle. 1981; 7(3):107-12. View

19.

Suri C, Jones P, Patan S, Bartunkova S, Maisonpierre P, Davis S . Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996; 87(7):1171-80. DOI: 10.1016/s0092-8674(00)81813-9. View

20.

Thurston G, Rudge J, Ioffe E, Zhou H, Ross L, Croll S . Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med. 2000; 6(4):460-3. DOI: 10.1038/74725. View